Roche says SMA drug meets trial goal

Roche said on Monday its drug risdiplam helped people with type 2 or 3 spinal muscular atrophy improve their motor function, as the Swiss drugmaker presses ahead with a medicine it sees rivaling Biogen's Spinraza and Novartis's Zolgensma.

from Reuters: Health News https://ift.tt/36WpjuK
via IFTTT